Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 13/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10269959 | 1.00 | HSD17B10 (0.42) | HSD17B10ESR1ESR2TTRCA12 | |
| SCHEMBL264135 | 0.86 | HSD17B10 (0.42) | HSD17B10ESR1ESR2TTRCA12 | |
| SCHEMBL30774096 | 0.86 | HSD17B10 (0.42) | HSD17B10ESR1ESR2TTRCA12 | |
| SCHEMBL5477046 | 0.81 | LPL (0.35) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15071862 | 0.81 | TSHR (0.39) | HSD17B10LPLLIPGJAK2BTK | |
| SCHEMBL29978910 | 0.80 | ESR2 (0.39) | HSD17B10ESR1ESR2CA12CA9 | |
| SCHEMBL257840 | 0.80 | ESR2 (0.39) | HSD17B10ESR1ESR2CA12CA9 | |
| SCHEMBL16688104 | 0.80 | LPL (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL462939 | 0.80 | JAK2 (0.36) | LPLLIPGJAK2BTK | |
| SCHEMBL1284567 | 0.79 | CYP3A4 (0.42) | HSD17B10CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4464700-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023134752-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-3349761-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | SRC, DSTYK, TUBB1 | HSD17B10 1840/4885ESR1 3726/4885ESR2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.